Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy

NCT00836160 is registered in ClinicalTrials.gov with AstraZeneca as lead sponsor.

NCT NCT00836160
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00836160 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Comparing Efficacy Between Anti-microtubule and Non-anti-microtubule as 3th Therapy After 2nd Line EGFR-TKI Therapy
Lead sponsor
AstraZeneca
Phase
Observational
Overall status
Completed
Start date
August 31, 2009
Completion date
September 30, 2012
Enrollment
36 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

cancer